A January 26, 2017 Alzheimer’s News Today story reports on a Phase 2 study led by 1998 Beeson Scholar R. Scott Turner, MD, PhD at Georgetown University Medical Center to study a cancer drug’s effect on Alzheimer’s disease.
With Turner serving as principal investigator, the study is recruiting participants for a clinical trial to evaluate the cancer drug Tasigna (nilotinib) in people with mild to moderate Alzheimer’s in order to evaluate how low doses of Tasigna impact safety, biomarkers, and clinical outcomes.
The Alzheimer's Drug Discovery Foundation is supporting this clinical trial through a $2.1 million grant to Turner.
Read the full article here.
R. Scott Turner, MD, PhD, is a Professor of Neurology at Georgetown University.
For expert-edited insights, read AFAR’s expert-edited InfoAging Guide to Alzheimer's Disease here.
